Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride
- 21 October 2021
- journal article
- research article
- Published by Elsevier BV in Life Sciences
- Vol. 286, 120070
- https://doi.org/10.1016/j.lfs.2021.120070
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Extracellular Matrix and Liver DiseaseAntioxidants and Redox Signaling, 2014
- Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinaseBiochemical Pharmacology, 2012
- AMP‐activated protein kinase inhibits TGF‐β‐induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300Journal of Cellular Physiology, 2011
- AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespanJournal of Molecular Medicine, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesisFibrogenesis & Tissue Repair, 2010
- Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase InhibitionGastroenterology, 2010
- The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- The value of α‐SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical studyHistopathology, 2005